Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

Definition

Category: Causal-framing concept

Also known as: telomere shortening, hallmark of aging

Telomere attrition is one of the recognised hallmarks of aging: telomeres shorten with each cell division (the end-replication problem) and with oxidative and replicative stress, and critically short telomeres trigger senescence or apoptosis. Whether telomere shortening is a primary driver of human aging or largely a downstream marker of it is still debated, and changing a telomere-length measurement in a trial does not establish an effect on human aging.

Key points

  • The hallmark framing is associative and mechanistic; it is not proof that lengthening telomeres in humans slows aging or extends lifespan.
  • Telomere length is a contested aging biomarker: it is measured differently by different methods, varies between tissues, and 'longer' is not straightforwardly 'healthier'.
  • This causal-framing page exists so that every intervention page can be read against the honest gap between 'changed a telomere number' and 'slowed human aging'.
  • Telomere-driven replicative senescence links this cluster to senesiq.com, which is cross-referenced rather than duplicated.

Sourcing

Synthesis of standard aging-biology reviews (Lopez-Otin et al. Hallmarks of Aging; Blasco telomere reviews). Review-level, not a primary numeric claim.

Reference synthesis (tier 5); verification: review_level_2026-07-12.